Shareholders of Northwest Bancshares (NWBI) must act before this Friday's ex-dividend date to secure the upcoming $0.20 per share payout, as the regional bank maintains a notable 6.2% yield amid questions about long-term payout sustainability.
Merck & Co. is set to report fourth-quarter 2025 results before the bell on Tuesday, with Wall Street anticipating steady growth. The pharmaceutical giant's shares have climbed 13% over the past year, outpacing the broader healthcare sector. All eyes will be on Keytruda's sales trajectory and management's guidance for the year ahead.
Shares of Japanese financial giant ORIX (TSE:8591) have shown mixed short-term performance, yet a deeper look reveals robust 90-day and one-year returns. With the stock trading at ¥4,627, analysts debate whether the market is overlooking intrinsic value or correctly pricing future growth amid a global shift towards alternative capital.
A significant reset in CareCloud's (CCLD) price target by analysts is prompting a fresh look at the healthcare IT firm's risk-reward profile. This shift reflects evolving perspectives on the company's trajectory and market position. We examine the catalysts for this change and its implications for investors.
New federal data reveals a significant year-over-year jump in energy costs for November, with natural gas prices soaring and electricity rates climbing, squeezing household budgets amid fluctuating demand and generation patterns.
Piper Sandler raises its price target on Kura Sushi USA (KRUS) following an investor meeting, citing potential from recent changes to its digital loyalty platform. The company also appointed a new marketing-focused director as it eyes U.S. expansion.
Stephens lowers price target on Cal-Maine Foods (CALM) citing near-term oversupply pressures, but the egg producer's long-term strategy remains focused on expanding its cage-free capacity through acquisition.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Morgan Stanley has upgraded Johnson & Johnson to 'Overweight,' raising its price target to $262, citing confidence in the healthcare giant's robust pipeline of new pharmaceuticals and medical devices.
A pivotal week for markets unfolds as Amazon, Alphabet, AMD, and Disney headline a packed earnings calendar. With implied volatility spiking, option traders brace for significant moves across sectors.
Zions Bancorporation has authorized a new $75 million stock repurchase program, a move analysts see as a bet on its undervalued shares and a commitment to shareholder returns as regional banks navigate a cautious regulatory environment.
Barclays reaffirms its Overweight rating on Meta Platforms, raising its price target to $800, citing robust Q4 recovery and surging ad revenue. The upgrade follows CEO Mark Zuckerberg's announcement of a massive $115B-$135B AI infrastructure investment plan for 2026.
A deep dive into valuation metrics suggests Martin Marietta Materials (MLM) shares may be pricing in an overly optimistic outlook for construction growth, with key models indicating potential overvaluation.
CME Group has increased margin requirements for precious metals futures and options following extreme price swings, as daily trading volumes hit record highs. The exchange is also introducing new silver products and enforcing compliance measures, highlighting its dual role as a market facilitator and risk manager during turbulent times.
While the German market gained a modest 7.7%, steel dust recycling leader Befesa (ETR:BFSA) delivered a total shareholder return of 54% over the past twelve months. This impressive rebound follows a challenging three-year period, sparking investor debate on whether it signals a sustained recovery or a temporary rally.
While low share prices often signal volatility, they can also hide significant upside. We analyze three companies trading under $10—Archer Aviation, Snap, and Opendoor Technologies—that are positioned to defy market expectations in the coming year, driven by sector tailwinds and strategic pivots.
A discounted cash flow analysis suggests Westinghouse Air Brake Technologies (Wabtec) shares may be trading at a premium. We break down the valuation model, its assumptions, and the broader market forces at play for the rail equipment leader.
A wave of insider selling at The Progressive Corporation, totaling over $16 million in the past year, has prompted investors to scrutinize the insurer's outlook. While such sales aren't uncommon, the scale and timing invite questions about internal confidence as the stock trades significantly below recent insider sale prices.
Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.
Insurance brokerage giant Arthur J. Gallagher reported robust fourth-quarter profit growth, driven by resilient demand. However, Truist Securities has lowered its price target on the stock, citing valuation pressures across the property & casualty brokerage sector.
